CA2695318A1 - Predictive marker for egfr inhibitor treatment - Google Patents

Predictive marker for egfr inhibitor treatment Download PDF

Info

Publication number
CA2695318A1
CA2695318A1 CA2695318A CA2695318A CA2695318A1 CA 2695318 A1 CA2695318 A1 CA 2695318A1 CA 2695318 A CA2695318 A CA 2695318A CA 2695318 A CA2695318 A CA 2695318A CA 2695318 A1 CA2695318 A1 CA 2695318A1
Authority
CA
Canada
Prior art keywords
patients
treatment
cancer
gene
egfr inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2695318A
Other languages
English (en)
French (fr)
Inventor
Paul Delmar
Barbara Klughammer
Verena Lutz
Patricia Mcloughlin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F. Hoffmann-La Roche Ag
Paul Delmar
Barbara Klughammer
Verena Lutz
Patricia Mcloughlin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag, Paul Delmar, Barbara Klughammer, Verena Lutz, Patricia Mcloughlin filed Critical F. Hoffmann-La Roche Ag
Publication of CA2695318A1 publication Critical patent/CA2695318A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2695318A 2007-08-14 2008-08-07 Predictive marker for egfr inhibitor treatment Abandoned CA2695318A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07114305.1 2007-08-14
EP07114305 2007-08-14
PCT/EP2008/006518 WO2009021679A1 (en) 2007-08-14 2008-08-07 Predictive marker for egfr inhibitor treamtent

Publications (1)

Publication Number Publication Date
CA2695318A1 true CA2695318A1 (en) 2009-02-19

Family

ID=39789783

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2695318A Abandoned CA2695318A1 (en) 2007-08-14 2008-08-07 Predictive marker for egfr inhibitor treatment

Country Status (9)

Country Link
EP (1) EP2176429A1 (de)
JP (1) JP2010535520A (de)
KR (1) KR20100037633A (de)
CN (1) CN101802221A (de)
AU (1) AU2008286412A1 (de)
BR (1) BRPI0815372A2 (de)
CA (1) CA2695318A1 (de)
MX (1) MX2010001572A (de)
WO (1) WO2009021679A1 (de)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646249A (en) * 1994-02-28 1997-07-08 The United States Of America As Represented By The Department Of Health And Human Services Isolation and characterization of a novel chaperone protein
WO2004111273A2 (en) * 2003-05-30 2004-12-23 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
EP2348110B1 (de) * 2003-05-30 2013-03-27 OncoTherapy Science, Inc. Prozess zum screening einer medikamentenansprache in krebspatienten

Also Published As

Publication number Publication date
WO2009021679A1 (en) 2009-02-19
BRPI0815372A2 (pt) 2019-09-24
MX2010001572A (es) 2010-03-15
JP2010535520A (ja) 2010-11-25
CN101802221A (zh) 2010-08-11
EP2176429A1 (de) 2010-04-21
AU2008286412A1 (en) 2009-02-19
KR20100037633A (ko) 2010-04-09

Similar Documents

Publication Publication Date Title
AU2008286335B2 (en) Predictive marker for EGFR inhibitor treatment
US20110218212A1 (en) Predictive markers for egfr inhibitors treatment
EP2179056B1 (de) Egfr-inhibitor-behandlungsmarker
US9121067B2 (en) Predictive marker for EGFR inhibitor treatment
US20110245279A1 (en) Predictive marker for egfr inhibitor treatment
EP2188393B1 (de) Prognosemarker zur behandlung mit egfr-hemmern
US20110312981A1 (en) Predictive marker for egfr inhibitor treatment
CA2695318A1 (en) Predictive marker for egfr inhibitor treatment
US20130217712A1 (en) Predictive marker for egfr inhibitor treatment
US20110184004A1 (en) Predictive marker for egfr inhibitor treatment
CA2695471A1 (en) Predictive marker for egfr inhibitor treatment

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead